Regulating HDAC6 Inhibits Tumor Skeleton Remodeling and Metastasis in Hepatocellular Carcinoma Microenvironment
Background: Limitations of Unidirectional Transcriptomic Profiling and Heterogeneous Epigenetic Data Bottlenecks in Hepatocellular Carcinoma R&D
- Conventional, static, and bulk transcriptomic profiling guidelines suffer from critical blind spots, failing to capture the extreme molecular heterogeneity and microenvironmental variability of hepatocellular carcinoma. Specifically, cell dissociation-induced structural disruption noise during tissue fragmentation and interspecies translational differences during ex vivo culture distort key indicators of the cytoskeletal mechanism, such as TUBA1A acetylation equilibrium and the physical gradient of CTNNB1, a core factor in the Wnt signaling pathway. Furthermore, the inability to computationally predict the tubulin deacetylation induced by cytoplasmic HDAC6 activity and the resulting Wnt inhibitory feedback flux leads to data bottlenecks, failing to secure effective therapeutic concentrations and prophylactic doses during initial screening. This represents a structural limitation of existing target validation methods that rely on static protein matrix analysis.
Discovery: In Silico Demonstration of Precise HDAC6-TUBA1A-CTNNB1 Tensor Synchronization and Network Topological Dynamics
- In this study, we implemented a transcriptome-methylation-protein tensor synchronization system by integrating large-scale multi-omics databases such as TCGA, GEO, and HPA, and removing batch effects. Through protein docking free-energy adjustment models and in silico calculations of differential equation-based reaction rate constants, we elucidated that downregulation of HDAC6 inhibits TUBA1A deacetylation, thereby impairing microtubule stability and promoting CTNNB1 nuclear translocation, leading to a disruptive activation of the Wnt signaling pathway. This architecture closely links HDAC6 expression levels with tumor-infiltrating cytotoxic immune cell clusters, demonstrating with molecular integrity that the HDAC6-TUBA1A-CTNNB1 axis is a topological core mechanism that determines an immunosuppressive microenvironment.
Establishment of a Cytoskeleton-Wnt Cross-Pathway Regulatory and Reversible Homeostatic Precision Stratification Model
- The constructed multi-omics matrix data serves as the basis for an architecture that clusters patients with hepatocellular carcinoma by family, enabling precision stratification based on their genetic and epigenetic patterns. By simulating in silico the induction of HDAC6 promoter demethylation and the up- and down-regulation of CTNNB1 methylation status, key steps in cancer development, we derived a precise control loop that reversibly regulates the physical homeostasis of tumor cell cytoskeletons under exogenous stress. This model maps the responsiveness of HDAC6-selective inhibitors, such as Ricolinostat (ACY-1215), and CTNNB1 downstream transcriptional inhibitors to patient gene topological variation curves, enabling high-resolution stratification of therapeutic response areas.
Prospects: Establishing a Programmable Computational Oncology Standard and Implementing a Next-Generation IND Digital Governance System
- This study presents a milestone in reshaping tumor R&D governance into a programmable computational systems biology standard infrastructure based on multidimensional tensor modeling. When developing global multinational pharmaceutical and biotechnology pipelines, linking the HDAC6-TUBA1A-CTNNB1 genetic gradient correction coefficient to high-throughput screening (HTS) computationally eliminates data distortion caused by batch effects between cell lines and patient-derived organoids. This fully meets the precise specification requirements of clinical companion diagnostics (CDx) products and standardizes data for Investigational New Drug (IND) submissions, potentially revolutionizing FDA review timelines and minimizing quality variations in cGMP processes.
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, characterized by marked molecular heterogeneity, late-stage diagnosis, and limited therapeutic options. Emerging evidence highlights the interplay between cytoskeletal dynamics, epigenetic regulation, and oncogenic signaling pathways in hepatocarcinogenesis. Histone deacetylase 6 (HDAC6), a key regulator of cytoplasmic protein acetylation, modulates ฮฑ-tubulin stability, while CTNNB1 (ฮฒ-catenin) serves as a central effector of the Wnt signaling pathway. However, the existence and functional relevance of a coordinated HDAC6-TUBA1A-CTNNB1 regulatory axis in HCC remain insufficiently explored. We conducted a comprehensive integrative bioinformatic analysis using multiple publicly available datasets and platforms, including TCGA, GEO, GEPIA3, TNMplot, UALCAN, TIMER2.0, STRING, ENCORI, HPA, TargetScan, miRDB, CRISPRdb, GSCALite, and exoRBase. Gene expression, promoter methylation, survival associations, immune infiltration, regulatory RNA interactions, and therapeutic targetability were systematically evaluated. HDAC6 expression was significantly downregulated in HCC tissues, whereas TUBA1A and CTNNB1 were upregulated. Reduced HDAC6 expression was associated with poorer survival outcomes, while TUBA1A and CTNNB1 showed no significant prognostic value. Methylation analysis revealed gene-specific epigenetic alterations, including hypomethylation of CTNNB1 and differential methylation patterns in HDAC6 and TUBA1A. Immune infiltration analysis demonstrated that HDAC6 expression positively correlated with cytotoxic immune cell populations and negatively with immunosuppressive subsets. Regulatory network analyses identified lncRNA-miRNA-mRNA interactions, particularly involving SNHG1. Furthermore, in silico CRISPR targetability and extracellular vesicle (EV) transcript profiling suggested potential translational applicability of this axis. Our findings support a hypothesis of the exist
The discovery of the HDAC6-TUBA1A-CTNNB1 regulatory axis in this study goes beyond theoretical exploration of epigenetic mechanisms and directly translates into the global market for targeted anticancer drugs and next-generation precision medicine business lines.
First, by instantly scanning the rate of HDAC6-mediated tubulin deacetylation in patient tissue using a Python algorithm, we can eliminate the temporal noise that causes microenvironmental metastasis and drug resistance, and protect against early diagnosis and prolonged survival in patients who do not respond to treatment.
At the same time, by linking to the open-source TCGA database, which aggregates whole-genome methylation datasets, we can virtually simulate patient-specific epigenetic variations that act as false-positive biomarkers during clinical trial design, and realize a companion diagnostic (CDx) panel interface that can calculate the effective docking concentration of HDAC6 target proteins in real time.
Furthermore, when multinational companies conduct large-scale clinical trials for next-generation hepatocellular carcinoma targeted therapies, linking the cytoplasmic acetylation transfer activity as a correction coefficient can eliminate batch-to-batch pharmacokinetic variability in effective drug response and maximize the probability of obtaining regulatory approvals from global regulatory agencies for clinical trial protocols and cGMP commercial operations, serving as a backbone infrastructure.